TARGETING PRMT3-IGF2BP1 AXIS-MEDIATED EPITRANSCRIPTOMIC REPROGRAMMING AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME IMMUNOTHERAPY RESISTANCE IN CCRCC
$1,144,500FY2025Defense Health AgencyDOD
The Univeristy Of Texas M.D. Anderson Cancer Center
The Univeristy Of Texas M.D. Anderson Cancer Center